Perrigo completes sale of Dermacosmetics business for €305.6M upfront, plus contingent €27M

PERRIGO Co plc

Upfront cash €305.6M (incl. €5.6M working capital); up to €27M contingent on net sales milestones over three years.
Brands sold: ACO, Biodermal, Emolium, Iwostin; business generated ~€120M net sales (~5% of adj. op income) in 2025.
Net proceeds will be used primarily for debt reduction, enhancing financial flexibility and strengthening balance sheet.
Divestiture is part of Perrigo's Three-S plan to Stabilize, Streamline, and Strengthen the Company.

item 2.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.